22.07.2013 Views

Brain Tumor and Neuro-Oncology Center - Cleveland Clinic

Brain Tumor and Neuro-Oncology Center - Cleveland Clinic

Brain Tumor and Neuro-Oncology Center - Cleveland Clinic

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

2008 ANNUAL REPORT<br />

<strong>Brain</strong> <strong>Tumor</strong> <strong>and</strong> <strong>Neuro</strong>-<strong>Oncology</strong> <strong>Center</strong> – Overview<br />

A Team Approach to Individualized Care<br />

Clevel<strong>and</strong> <strong>Clinic</strong> <strong>Brain</strong> <strong>Tumor</strong> <strong>and</strong> <strong>Neuro</strong>-<strong>Oncology</strong><br />

<strong>Center</strong> (BTNC) is a national leader in the diagnosis,<br />

treatment <strong>and</strong> research of brain tumors. The unique<br />

administrative structure of the BTNC allows our<br />

multidisciplinary team of physicians <strong>and</strong> scientists to<br />

focus almost exclusively on brain tumors, facilitating<br />

opportunities for our staff to participate in international<br />

research protocols, share information about the latest<br />

developments in the field <strong>and</strong> combine therapeutic<br />

approaches from a number of disciplines. The result is<br />

the ability to bring the most promising new treatments<br />

to the clinical realm in an environment that facilitates<br />

individualized patient care.<br />

The BTNC has been a member of the prestigious<br />

New Approaches to <strong>Brain</strong> <strong>Tumor</strong> Therapy (NABTT)<br />

consortium for more than seven years. The primary<br />

objective of the National Cancer Institute-sponsored<br />

NABTT consortium is to improve the therapeutic<br />

outcome for adults with primary brain tumors while<br />

sharing human brain tumor specimens <strong>and</strong> clinical<br />

<strong>and</strong> laboratory data to facilitate additional research<br />

pertaining to basic biology <strong>and</strong> neuro-pharmacology<br />

of new treatments. To qualify for NABTT membership,<br />

an institution must possess strong clinical <strong>and</strong> research<br />

programs for adult brain tumors, expert multidisciplinary<br />

clinical teams, extensive laboratory <strong>and</strong> clinical<br />

resources, <strong>and</strong> the ability to conduct high-quality,<br />

clinically relevant trials. In 2008, we were honored<br />

to be selected as a charter member of the new Adult<br />

<strong>Brain</strong> <strong>Tumor</strong> Consortium, which supersedes the NABTT<br />

consortium in 2009.<br />

Building on the strong tradition of excellence <strong>and</strong><br />

innovation established by members of the BTNC team,<br />

the future of clinical application <strong>and</strong> ongoing research<br />

at Clevel<strong>and</strong> <strong>Clinic</strong> is both bright <strong>and</strong> exciting. We<br />

aim to streamline the process of bringing potentially<br />

groundbreaking therapeutic agents from the laboratory<br />

to the patient, making new chemotherapeutic agents,<br />

radiosurgical techniques <strong>and</strong> surgical procedures<br />

available more quickly, while maintaining the highest<br />

scientific st<strong>and</strong>ards for both efficacy <strong>and</strong> safety.<br />

5

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!